N/A N=61 Randomized Quadruple-blind Treatment

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

Bottom Line

View on ClinicalTrials.gov: NCT00382824 ↗

Enrolled (actual)

Serious AEs

21.3%

Results posted

Aug 2019

Primary outcome: Primary: Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS]) — 5.9; 11.8; 11.5; 12.8 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Coenzyme Q10 (Dietary_supplement); Placebo (Other)
Age: Adult, Older Adult · 30+ yrs
Sex: All
Sponsor: Lahey Clinic
Primary completion: Sep 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS])	5.9; 11.8; 11.5; 12.8	—
SECONDARY Efficacy of Coenzyme Q10 (Mini-Mental State Examination [MMSE] and Activities of Daily Living [ADL] Scales)	-13.5; -18.4; -1.3; -1.3	—
SECONDARY Quality of Life Questionnaires: Parkinson's Disease Questionnaire - 39 [PDQ-39], Short Form-36 [SF-36]	3.4; 7.5; -2.1; -7.2	—
SECONDARY Safety Profile of Coenzyme Q10	27; 38; 5; 8	—
SECONDARY Tolerability of Coenzyme Q10	20; 16	—

Summary

The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).

Eligibility Criteria

Inclusion Criteria

Patients fulfilling the diagnostic criteria of PSP/diagnosed within the past 5 years
Either vertical supranuclear palsy or both slowing of vertical saccades
Prominent postural instability with falls in the first year of disease onset
No evidence of other diseases that could explain the foregoing features

Exclusion Criteria

Current or previous therapeutic use of CoQ10
Parkinsonism due to drugs
History of pallidotomy, thalamotomy, active deep brain stimulator or fetal tissue transplant
History of active epilepsy, stroke, structural brain disease
Use of methylphenidate hydrochloride, cinnarizine, reserpine, amphetamines, or monoamine oxidase-A inhibitors within 3 months before the baseline visit.
Active cancer or cancer undergoing treatment
Participation in other drug studies or the use of other investigational drugs within 30 days before screening.
Known hypersensitivity to Coenzyme Q10.
Pregnant, planning a pregnancy or nursing woman

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00382824). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.